Patients with T2D who received GLP-1RAs or SGLT2 inhibitors were not associated with an increased risk for ARDs compared with DPP4 inhibitors.

Australia's Therapeutic Goods Administration (TGA), responsible for approval ofthe safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Tirzepatide use is linked to lower risks of incident and progressive diabetic retinopathy compared with lifestyle intervention alone.

Concurrent hormone therapy may augment the cardiometabolic benefits of tirzepatide, including improved blood pressure and lipid profiles.

Comparable long-term effectiveness to classic corticosteroids, both prednisone (p=0.8587) and deflazacort (p=0.6544), based on time to loss of ...

Results from Asia suggest chronic rhinosinusitis is associated with an increased risk for cancer, but whether these results ...

Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Among patients with asthma without diabetes, the risk for exacerbation was decreased with GLP-1 receptor agonist exposure, ...

year findings call for physicians to balance the benefits of the medication for weight loss with the rupture risks, particularly for tendons that do the heavy lifting.